News Release

We are excited to announce that CanVirex has moved forward in the development of its lead candidate Mevacil for the treatment of cancer. CanVirex is in preparation of a phase I/IIa trial to assess safety and tolerability of Mevacil in patients with advanced-stage solid cancers. Mevacil is a proprietary, oncolytic measles virus that encodes the …

News Release Read More »